Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02885974 · ClinicalTrials.gov registry record · Phase 1
Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer
A Phase 1 study of Bladder Cancer, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 2
- Study locations
NCT02885974 is a Phase 1 study of Bladder Cancer that has completed, run by Baylor College of Medicine. The registered enrollment target is 22 participants, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02885974, a Phase 1 study of Bladder Cancer, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to compare patient tumor tissue before and after treatment with chemotherapy plus celecoxib. Investigators will look at gene expression, to see what effect celecoxib may have on tumor cells.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Celecoxib
- DRUG Gemcitabine
Study Locations (2)
Texas
- Baylor Clinic - Houston
- Harris Health System - Smith Clinic - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-12 |
| Est. Completion | 2025-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02885974
The ClinicalTrials.gov registry entry for NCT02885974 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT02885974 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02885974 about?
NCT02885974 is a clinical study titled "Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer". The purpose of this study is to compare patient tumor tissue before and after treatment with chemotherapy plus celecoxib. Investigators will look at gene expression, to see what effect celecoxib may have on tumor cells.
What is the current status of trial NCT02885974?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2016-12. Estimated completion is 2025-03.
What conditions does trial NCT02885974 study?
This clinical trial studies the following conditions: Bladder Cancer.
What interventions are being tested in trial NCT02885974?
The interventions under investigation include: Cisplatin (DRUG), Celecoxib (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT02885974?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02885974 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Sacituzumab Govitecan Plus EV in Metastatic UC
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.